Portal de investigación
Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno-based regimens
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Moura, DS
- Mondaza-Hernandez, JL
- Shirikova, A
- Romero-Gonzalez, P
- Carrera, M
- Rodriguez, C
- Martínez-Trufero, J
- Sebio, A
- Jurado, JC
- Valverde, C
- Carrasco-Garcia, I
- Gonzalez-Billalabeitia, E
- Fernandez-Jara, J
- Lopez-Jimenez, C
- Hindi, N
- Gutierrez, A
- Broto, JM
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0732-183X, 1527-7755
- Tipo:
- Meeting Abstract
- Páginas:
- 23526-23526
- Factor de Impacto:
- 9,378 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF CLINICAL ONCOLOGY LIPPINCOTT WILLIAMS & WILKINS
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Cita
Moura,DS,Mondaza,JL,Shirikova,A,Romero,P,Carrera,M,Rodriguez,C,Martínez,J et al. Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno-based regimens. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2026. Chicago. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2026 p.p. 23526-23526.